COMMUNIQUÉS West-GlobeNewswire

Allogene Therapeutics Announces Participation in September Investor Conference
31/08/2026
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for [...]
Arch Biopartners Receives Central IRB Approval to Support U.S. Sites in Phase II Cardiac Surgery-Associated Acute Kidney Injury Trial of LSALT Peptide
31/08/2026
TORONTO, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc . (TSX Venture: ARCH and OTCQB: ACHFF) today announced that it has received central Institutional Review Board (“IRB”) approval of the protocol and related [...]
Amarin Highlights New REDUCE-IT® and Mechanistic Data Presented at European Society of Cardiology (ESC) Congress 2026
31/08/2026
Presentations Expand Understanding of Treatment Adherence, Long-Term Outcomes, Lipoprotein(a), Coagulation Biomarkers, and Potential Mechanisms of Eicosapentaenoic Acid (EPA) 2026 ESC/ European Renal Association (ERA) [...]
OnKure Therapeutics to Participate in the Morgan Stanley Global Healthcare Conference
31/08/2026
BOULDER, Colo., Aug. 31, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines, today announced that senior [...]
Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference
31/08/2026
BOSTON, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, [...]
Sofwave Announces Publication of Data from Randomized Controlled Study of its Pure Impact™ VIP Platform Utilizing PlyoPulse™ EMS Technology in Aesthetic Surgery Journal
31/08/2026
A prospective randomized controlled trial of an aesthetic EMS platform to assess objective functional performance reports improvements across four standardized tests SAN CLEMENTE, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE [...]
Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Thrombocytopenia
31/08/2026
FDA Alignment on Primary Endpoint and Path Forward for Phase 3 Registration Study CAD-1005 Targets a Significant Unmet Need, with Approximately 50,000 Confirmed Acute HIT Diagnoses Annually in the U.S. and an Estimated [...]
Beyond Air® Receives FDA Breakthrough Device Designation for LungFit® GO to Treat Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)
31/08/2026
GARDEN CITY, N.Y., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of [...]
BioVie Announces Completion of Treatment Phase of ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
31/08/2026
Last Patient Last On-Site Visit Completed with Topline Data Release Targeted September 2026 CARSON CITY, Nev., Aug. 31, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage [...]
AEON Biopharma to Participate in Lake Street Capital Markets’ 10th Annual Best Ideas Growth (BIG10) Conference
31/08/2026
ALISO VIEJO, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX ® (onabotulinumtoxinA) [...]
Revelyx Bio Launches to Advance YY003, an Investigational Recombinant Botulinum Toxin Type A in a Ready-to-Use Liquid Formulation
31/08/2026
Company aims to deliver the first FDA-approved recombinant botulinum neurotoxin type A (rBoNT/A) Phase II study in moderate-to-severe glabellar lines completed; topline data expected in Q3 2026 Dustin Sjuts, former [...]
ORYZON Announces Notice of Allowance for U.S. Patent Application Covering Iadademstat Combination With Gilteritinib
31/08/2026
Iadademstat is under clinical development in acute myeloid leukemia (AML), including in combination with gilteritinib in the Phase Ib FRIDA trial in patients with FLT3-mutated relapsed/refractory (R/R) AML FRIDA data [...]
Chemomab Therapeutics to Present at H.C. Wainwright 28th Annual Global Investor Conference
31/08/2026
TEL AVIV, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for immune-fibrotic diseases with high [...]
Alpha Tau Completes Patient Enrollment in its Multicenter IMPACT Pancreatic Cancer Pilot Study of Alpha DaRT® Following Strong Demand and Multiple Expansions
31/08/2026
- IMPACT, a multicenter pilot study of Alpha DaRT ® for newly diagnosed unresectable pancreatic cancer, expanded enrollment three times over the course of the study, from an original enrollment of 12 patients to a total [...]
Teladoc Health Appoints Michael Grasher as Chief Financial Officer
31/08/2026
Appointment brings seasoned financial leadership as Teladoc Health advances its strategy aimed at delivering disciplined, sustainable growth NEW YORK, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC [...]
Emergent BioSolutions Awarded Government of Canada Standing Offer for NARCAN® Nasal Spray
31/08/2026
Standing offer expands access to opioid overdose emergency treatment across participating federal, provincial and territorial organizations in Canada WINNIPEG, Manitoba, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Emergent [...]
Emergent BioSolutions Reinforces Commitment to Opioid Overdose Education and Preparedness on International Overdose Awareness Day
31/08/2026
Ready to Rescue campaign returns to U.S. college campuses with Release Recovery Founder and CEO Zac Clark Partnership with professional baseball player Davis Schneider seeks to raise awareness of opioid poisoning [...]
NurExone Biologic Inc. Announces Second Quarter 2026 Financial Results
31/08/2026
TORONTO and HAIFA, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”), a biotechnology company developing exosome-based regenerative [...]
SRX Global Acquires Senior Secured Debt in CERo Therapeutics Holdings, Inc., an Innovative Cellular Immunotherapy Company with Cancer Fighting Molecule for the Treatment of Hematologic Cancers
31/08/2026
The Debt investment is expected to accelerate development of CERo's lead therapeutic CER-1236 for hematological cancers NORTH PALM BEACH, Fla., Aug. 31, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) ( [...]

Pages